The Bushell Chair of Neurology at the University of Sydney offered his perspective on phase 2 data of CNM-Au8 in amyotrophic lateral sclerosis and spoke to the advances that the field has made in recent years. [WATCH TIME: 3 minutes]
Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS
Advertisement
Bushell Chair of Neurology; Professor of Medicine, Central Clinical School; Codirector, Discovery and Translation, Brain and Mind Centre; NHMRC Practitioner Fellow, University of Sydney; Neurologist, Institute of Clinical Neurosciences, Royal Prince Alfred Hospital
Articles by Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS
CNM-Au8 Data From the RESCUE-ALS Open-Label Extension: Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS
The Bushell Chair of Neurology at the University of Sydney shared his insight into the latest data on CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis and the frameshift in treatment that it represents. [WATCH TIME: 3 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Paraneoplastic Neurologic Syndromes Present Before Testicular Germ Cell Tumor Diagnosis, Study Shows
2
NeurologyLive® Brain Games: October 26, 2025
3
Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia
4
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
5
